Last reviewed · How we verify

Epinephrine 0.03

Kasr El Aini Hospital · FDA-approved active Small molecule Quality 2/100

Epinephrine 0.03 is a Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved. Also known as: adrenaline.

At a glance

Generic nameEpinephrine 0.03
Also known asadrenaline
SponsorKasr El Aini Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epinephrine 0.03

What is Epinephrine 0.03?

Epinephrine 0.03 is a Small molecule drug developed by Kasr El Aini Hospital.

Who makes Epinephrine 0.03?

Epinephrine 0.03 is developed and marketed by Kasr El Aini Hospital (see full Kasr El Aini Hospital pipeline at /company/kasr-el-aini-hospital).

Is Epinephrine 0.03 also known as anything else?

Epinephrine 0.03 is also known as adrenaline.

What development phase is Epinephrine 0.03 in?

Epinephrine 0.03 is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing